China Pharma Inc. (CPHI)
AMEX: CPHI
· Real-Time Price · USD
1.91
-0.04 (-2.05%)
At close: Sep 26, 2025, 3:59 PM
1.87
-1.88%
After-hours: Sep 26, 2025, 05:30 PM EDT
China Pharma Revenue Breakdown
| Period Ending | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
|---|---|---|---|
| DomesticPharmaceuticalsMember Revenue | 2.89M | 1.98M | 2.42M |
| DomesticPharmaceuticalsMember Revenue Growth | +46.03% | -18.09% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 542.13K | 594.29B | 1.03M | 479.65K | 203.32K | 596.64K | 895.52K | 452.79K | 281.85K | 562.43K | 1.18M | 535.99K | 535.15K | 688.21K | 1.15M | 436.26K | 770.49K | 787.33K | 1.33M | 944.68K | 1.04M | 714.65K | 1.95M | 946.94K | 840.42K | 907.51K | 1.67M | 1.25M | 1.07M | 1.17M | 1.9M | 1.04M | 1.42M | 1.13M | 2.15M | 1.22M | 1.64M | 1.87M | 5.82M | 1.62M | 3.57M | 8.57M |
| Selling, General, and Administrative Revenue Growth | -100.00% | +57477713.28% | +115.56% | +135.91% | -65.92% | -33.37% | +97.78% | +60.65% | -49.89% | -52.49% | +120.84% | +0.16% | -22.24% | -40.01% | +162.96% | -43.38% | -2.14% | -40.74% | +40.64% | -9.58% | +46.19% | -63.30% | +105.64% | +12.68% | -7.39% | -45.79% | +33.61% | +17.16% | -8.77% | -38.14% | +82.95% | -26.82% | +24.77% | -47.36% | +76.40% | -25.45% | -12.31% | -67.90% | +259.01% | -54.62% | -58.29% | n/a |
| Research and Development Revenue | 20.95K | 29.59B | 547 | 87.61K | 164.33K | 31.45K | 147.55K | 45.77K | 23.75K | 23.01K | 28K | 88.75K | 15.06K | 54.05K | 54.05K | 21.37K | 53.46K | 190.09K | 261.47K | 37.63K | 30.04K | 48.82K | 53.99K | 39.72K | 66.01K | 69.92K | 64.44K | 62.06K | 23.67K | 22.21K | 15.42K | 27.54K | 21.45K | 26.06K | 76.78K | 99.09K | 96.66K | 93.43K | 220.78K | 405.44K | 174.85K | 160.83K |
| Research and Development Revenue Growth | -100.00% | +5408957852.47% | -99.38% | -46.69% | +422.51% | -78.68% | +222.36% | +92.75% | +3.21% | -17.83% | -68.45% | +489.17% | -72.13% | 0.00% | +152.87% | -60.02% | -71.88% | -27.30% | +594.89% | +25.24% | -38.46% | -9.59% | +35.95% | -39.83% | -5.59% | +8.51% | +3.83% | +162.14% | +6.58% | +44.04% | -44.01% | +28.41% | -17.69% | -66.06% | -22.52% | +2.52% | +3.45% | -57.68% | -45.55% | +131.88% | +8.72% | n/a |
| Sales and Marketing Revenue | 101.29K | 87.11B | 174.58K | 134.6K | 111.45K | 108.19K | 259.55K | 206.52K | 169.82K | 144.43K | 364.4K | 259.38K | 266.45K | 179.56K | 536.9K | 134.29K | 445.48K | 378.33K | 507.57K | 654.09K | 727.64K | 326.1K | 754.94K | 613.11K | 505.87K | 478.69K | 896.31K | 925.65K | 716.22K | 678.33K | 1.25M | 686.83K | 803.43K | 717.64K | 1.28M | 927.19K | 857.69K | 968.51K | 1.14M | 1.16M | 1.01M | 988.95K |
| Sales and Marketing Revenue Growth | -100.00% | +49897654.03% | +29.70% | +20.77% | +3.02% | -58.32% | +25.68% | +21.61% | +17.58% | -60.36% | +40.49% | -2.66% | +48.39% | -66.56% | +299.80% | -69.85% | +17.75% | -25.46% | -22.40% | -10.11% | +123.14% | -56.81% | +23.13% | +21.20% | +5.68% | -46.59% | -3.17% | +29.24% | +5.59% | -45.85% | +82.39% | -14.51% | +11.96% | -44.07% | +38.40% | +8.10% | -11.44% | -14.90% | -1.48% | +14.09% | +2.38% | n/a |